Envestnet Asset Management Inc. Purchases 12,671 Shares of Hologic, Inc. (NASDAQ:HOLX)

Envestnet Asset Management Inc. lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 361,271 shares of the medical equipment provider’s stock after purchasing an additional 12,671 shares during the period. Envestnet Asset Management Inc.’s holdings in Hologic were worth $26,824,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Innealta Capital LLC bought a new stake in shares of Hologic in the second quarter valued at about $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic during the first quarter worth approximately $37,000. Mather Group LLC. acquired a new stake in shares of Hologic in the first quarter valued at approximately $48,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the period. Finally, Toth Financial Advisory Corp grew its position in Hologic by 81.1% during the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 347 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on HOLX. Stephens reaffirmed an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Tuesday, September 17th. Evercore ISI increased their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Finally, StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Price Performance

Hologic stock opened at $81.39 on Friday. The stock has a 50-day moving average price of $80.82 and a two-hundred day moving average price of $77.12. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a market capitalization of $18.99 billion, a PE ratio of 41.53, a P/E/G ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $0.93 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 over the last 90 days. 1.75% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.